A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers

被引:126
作者
Yokoi, S
Yasui, K
Saito-Ohara, F
Koshikawa, K
Iizasa, T
Fujisawa, T
Terasaki, T
Horii, A
Takahashi, T
Hirohashi, S
Inazawa, J [1 ]
机构
[1] Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, Tokyo 1138519, Japan
[2] Chiba Univ, Grad Sch Med, Dept Thorac Surg, Chiba, Japan
[3] Aichi Canc Ctr, Res Inst, Div Mol Oncol, Nagoya, Aichi 464, Japan
[4] Aichi Canc Ctr, Res Inst, Div Immunol, Nagoya, Aichi 464, Japan
[5] Natl Canc Ctr, Res Inst, Div Pathol, Tokyo 104, Japan
[6] Tohoku Univ, Grad Sch Med, Dept Mol Pathol, Sendai, Miyagi 980, Japan
关键词
D O I
10.1016/S0002-9440(10)64172-7
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
We investigated DNA copy-number aberrations in 22 cell lines derived from small cell lung cancers (SCLCs) using comparative genomic hybridization. A minimal common region at 5p13, within the 5p11-p13 amplicon that was most frequently involved, harbored the CDH6, PC4, and SKP2 genes. These three genes showed amplification and consequent overexpression in the SCLC cell lines. SKP2 positively regulates progression of cell cycle by targeting several regulators, such as the cell-cycle inhibitor p27(KIP1), for ubiquitin-mediated degradation. SKP2 was amplified in 7 (44%) of 16 primary SCLC tumors, and consequently overexpressed in 10 (83%) of the 12 of those tumors we examined. Expression levels of SKP2 protein were cell cycle-dependent in SCLC cells as well as in normal cells, and were correlated with the DNA copy-number of the gene. There was an inverse correlation between the expression of SKP2 and p27(KIP1) proteins. Downregulation of SKP2 using an anti-sense oligonucleotide remarkably suppressed the growth of SCLC cells. Our results indicate that SKP2 is likely to be a target of the 5p13 amplification and to play an important role in the growth of SCLC cells.
引用
收藏
页码:207 / 216
页数:10
相关论文
共 67 条
[1]   CLONAL ORIGIN OF PHILADELPHIA-CHROMOSOME NEGATIVE CELLS WITH TRISOMY-8 APPEARING DURING THE COURSE OF ALPHA-INTERFERON THERAPY FOR PH POSITIVE CHRONIC MYELOCYTIC-LEUKEMIA [J].
ARIYAMA, T ;
INAZAWA, J ;
UEMURA, Y ;
KAKAZU, N ;
MAEKAWA, T ;
URASE, F ;
IRIMAJIRI, K ;
HORIUCHI, A ;
NAKAMURA, Y ;
ABE, T .
CANCER GENETICS AND CYTOGENETICS, 1995, 81 (01) :20-23
[2]   Identification of amplified DNA sequences on double minute chromosomes in a leukemic cell line KY821 by means of spectral karyotyping and comparative genomic hybridization [J].
Ariyama, Y ;
Sakabe, T ;
Shinomiya, T ;
Mori, T ;
Fukuda, Y ;
Inazawa, J .
JOURNAL OF HUMAN GENETICS, 1998, 43 (03) :187-190
[3]   EXPERIMENTAL PARAMETERS AND A BIOLOGICAL STANDARD FOR ACRIDINE-ORANGE DETECTION OF DRUG-INDUCED ALTERATIONS IN CHROMATIN CONDENSATION [J].
BLOCK, AL ;
BAUER, KD ;
WILLIAMS, TJ ;
SEIDENFELD, J .
CYTOMETRY, 1987, 8 (02) :163-169
[4]   STUDIES ON SYNCHRONOUS DIVISION OF TISSUE CULTURE CELLS INITIATED BY EXCESS THYMIDINE [J].
BOOTSMA, D ;
VOS, O ;
BUDKE, L .
EXPERIMENTAL CELL RESEARCH, 1964, 33 (1-2) :301-&
[5]   SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27 [J].
Carrano, AC ;
Eytan, E ;
Hershko, A ;
Pagano, M .
NATURE CELL BIOLOGY, 1999, 1 (04) :193-199
[6]  
Chao Y, 1998, CANCER RES, V58, P985
[7]  
*FDN PROM CANC RES, 1999, ED BOARD CANC CTR ST, P12
[8]  
Fukuda Y, 2000, GENE CHROMOSOME CANC, V29, P315, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1047>3.0.CO
[9]  
2-E
[10]   Skp2 is oncogenic and overexpressed in human cancers [J].
Gstaiger, M ;
Jordan, R ;
Lim, M ;
Catzavelos, C ;
Mestan, J ;
Slingerland, J ;
Krek, W .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (09) :5043-5048